Achillion Pharmaceuticals, Inc. (ACHN) Expected to Announce Earnings of -$0.14 Per Share

Equities analysts expect that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will report earnings of ($0.14) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Achillion Pharmaceuticals’ earnings. Achillion Pharmaceuticals posted earnings of ($0.12) per share during the same quarter last year, which would suggest a negative year over year growth rate of 16.7%. The business is scheduled to report its next earnings results on Wednesday, August 14th.

On average, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.59) per share for the current year. For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.67) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Achillion Pharmaceuticals.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14).

Several research firms have recently weighed in on ACHN. BidaskClub upgraded Achillion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 14th. Barclays downgraded Achillion Pharmaceuticals from an “equal weight” rating to an “underweight” rating and cut their price target for the stock from $5.00 to $2.50 in a research note on Friday, May 3rd. Zacks Investment Research downgraded Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 20th. Finally, William Blair reiterated an “outperform” rating on shares of Achillion Pharmaceuticals in a research note on Thursday, March 7th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. Achillion Pharmaceuticals has an average rating of “Hold” and a consensus target price of $2.50.

Shares of ACHN stock traded up $0.08 on Monday, hitting $2.86. 724,161 shares of the stock were exchanged, compared to its average volume of 1,702,364. The company has a market capitalization of $385.67 million, a price-to-earnings ratio of -5.61 and a beta of 2.34. Achillion Pharmaceuticals has a one year low of $1.29 and a one year high of $3.98.

Institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC purchased a new stake in Achillion Pharmaceuticals during the 1st quarter worth about $33,000. Acadian Asset Management LLC purchased a new stake in Achillion Pharmaceuticals during the 4th quarter worth about $41,000. Meeder Asset Management Inc. lifted its holdings in Achillion Pharmaceuticals by 107.3% during the 4th quarter. Meeder Asset Management Inc. now owns 26,476 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 13,706 shares in the last quarter. Norges Bank purchased a new stake in Achillion Pharmaceuticals during the 4th quarter worth about $55,000. Finally, Parametric Portfolio Associates LLC lifted its holdings in Achillion Pharmaceuticals by 21.4% during the 1st quarter. Parametric Portfolio Associates LLC now owns 21,014 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 3,700 shares in the last quarter. 79.30% of the stock is currently owned by institutional investors and hedge funds.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

Read More: Using other technical indicators with support levels

Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply